Catalent News

Express News | NYSE Order Imbalance 158865.0 Shares on Sell Side

Moomoo 24/7Apr 24 15:50 ET

Goldman's Debt Issuers Stocks Basket

Seeking AlphaApr 22 12:53 ET

Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating

BMO Capital Markets initiated coverage on Danish drug maker Novo Nordisk A/S (NYSE:NVO) after the company garnered interest as it hit the holy grail with the next generation of famed weight loss and d

BenzingaApr 12 13:22 ET

Zacks Investment Research Downgrades Catalent to Underperform From Neutral, Price Target Is $48

Zacks Investment Research Downgrades Catalent to Underperform From Neutral, Price Target is $48.

MT NewswiresApr 12 10:36 ET

Analysts Offer Insights on Healthcare Companies: Catalent (CTLT), Vertex Pharmaceuticals (VRTX) and Alkermes (ALKS)

TipRanksApr 12 01:41 ET

Express News | NYSE Order Imbalance 78033.0 Shares on Buy Side

Moomoo 24/7Apr 11 15:50 ET

Top 10 Best Performing S&P 500 Health Care Stocks of 2024

Seeking AlphaApr 10 14:56 ET

Novo Nordisk Parent Resubmits Application Seeking US Antirust Nod for Catalent Deal

Novo Nordisk (NOVO-B.CO) parent Novo Nordisk Foundation filed a new application to secure the US Federal Trade Commission's approval on its proposed acquisition of manufacturing subcontractor Catalent

MT NewswiresApr 9 00:05 ET

Sector Update: Health Care Stocks Decline Late Afternoon

Health care stocks were easing late Monday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each down about 0.2% The iShares Biotechnology ETF (IBB) rose 0.

MT NewswiresApr 8 16:00 ET

Sector Update: Health Care Stocks Flat to Higher Premarket Monday

Health care stocks were flat to higher premarket Monday, with the iShares Biotechnology ETF (IBB) inactive and the Health Care Select Sector SPDR Fund (XLV) up 0.1%. Alnylam Pharmaceuticals (ALNY) was

MT NewswiresApr 8 09:28 ET

Novo Nordisk Parent Refiles US Application on Catalent Deal

Yahoo FinanceApr 8 06:31 ET

Ares, Blue Owl Lead $4.8 Billion Private Debt for Catalent Deal

BNN BloombergApr 5 16:55 ET

Analysts Have Conflicting Sentiments on These Healthcare Companies: Catalent (CTLT), Alvotech (ALVO) and Immunocore Holdings (IMCR)

TipRanksApr 5 03:50 ET

Beyond The Numbers: 6 Analysts Discuss Catalent Stock

In the preceding three months, 6 analysts have released ratings for Catalent (NYSE:CTLT), presenting a wide array of perspectives from bullish to bearish.The following table encapsulates their recent

BenzingaApr 4 11:01 ET

Catalent Price Target Maintained With a $63.50/Share by Stephens & Co.

Catalent Price Target Maintained With a $63.50/Share by Stephens & Co.

Dow JonesApr 4 10:36 ET

Express News | Stephens & Co. Reiterates Equal-Weight on Catalent, Maintains $63.5 Price Target

Moomoo 24/7Apr 4 10:26 ET

Catalent Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/04/2024 12.13% Stephens & Co. → $63.5 Reiterates Equal-Weight → Equal-Weight 02/20/2024 12.13% RBC Capi

BenzingaApr 4 10:24 ET

Express News | Invenra To Collaborate With Catalent To Co-Discover Novel Bispecific ADCs

Moomoo 24/7Apr 2 13:59 ET

Invenra Inc. Announces a Strategic Collaboration With Catalent to Co-Discover Novel Bispecific ADCs

Invenra Inc., an innovative leader in bispecific antibody technology, is pleased to announce a strategic collaboration with Catalent, a global Contract Development and Manufacturing Organization (CDMO) specializing in

BusinesswireApr 2 13:54 ET

Aseptic Fill Finish Market Trends, Forecast and Competitive Analysis to 2030, Featuring AbbVie, Asymchem, Aenova, APL, BioPharma Solutions, BioReliance, Boehringer Ingelheim and Catalent Biologics

Yahoo FinanceApr 2 09:25 ET